Soleno Therapeutics Announces U.S. FDA Approval of VYKATTM XR to Treat Hyperphagia in Prader-Willi Syndrome
Portfolio Pulse from
Soleno Therapeutics (SLNO) received FDA approval for VYKAT XR, the first therapy to treat hyperphagia in Prader-Willi Syndrome (PWS) for adults and children 4 years and older. The drug is expected to be available in April 2025, addressing a critical unmet medical need for PWS patients.
March 26, 2025 | 9:30 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
FDA approval of VYKAT XR represents a significant milestone for Soleno, potentially driving stock value through first-to-market advantage in treating PWS hyperphagia.
FDA approval validates Soleno's drug development, opens new revenue stream, and positions company as leader in rare disease treatment market
CONFIDENCE 85
IMPORTANCE 90
RELEVANCE 100